Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ: LEGN )

37.85 -0.39 (-1.01%)
Streaming Delayed Price Updated: 3:39 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
Earnings Scheduled For March 11, 2025
Via Benzinga
Is Legend Biotech Gaining or Losing Market Support?
Via Benzinga
Peering Into Legend Biotech's Recent Short Interest
Via Benzinga
Where Legend Biotech Stands With Analysts
Via Benzinga
Breaking Down Legend Biotech: 9 Analysts Share Their Views
Via Benzinga
(LEGN) - Analyzing Legend Biotech's Short Interest
Via Benzinga
Deep Dive Into Legend Biotech Stock: Analyst Perspectives (10 Ratings)
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
9 Analysts Have This To Say About Legend Biotech
Via Benzinga
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients
Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly extends survival in multiple myeloma patients, reducing the risk of death by... 
Via Benzinga
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma
Legend Biotech said its J&J-partnered CAR-T drug cut the risk of death by 45% over standard treatment for multiple myeloma. 
Via Investor's Business Daily
Where Legend Biotech Stands With Analysts
Via Benzinga
Peering Into Legend Biotech's Recent Short Interest
Via Benzinga
Beyond The Numbers: 14 Analysts Discuss Legend Biotech Stock
Via Benzinga
Looking Into Legend Biotech's Recent Short Interest
Via Benzinga
Beyond The Numbers: 15 Analysts Discuss Legend Biotech Stock
Via Benzinga
LEGN Stock Earnings: Legend Biotech Beats EPS, Beats Revenue for Q2 2024
LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation?
Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its... 
Via Benzinga
Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?
Top performers last week: $WBD up 18.28%, $MSTR up 16.74%, $DHI up 12.91%, $COIN up 12.39%, $OQL up 7.89%, $UNH up 7.84%, $STT up 7.21%, $LEN up 7.07%, $TOST up 7.05%, $EPAM up 6.97%. Are they in your... 
Via Benzinga
Week In Review: Korea's SK Biopharma Acquires Radiopharmaceutical In $571 Million Deal
In recent news, South Korea’s SK Biopharma in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies of Shanghai in a $571 million deal. 
Via Talk Markets
The Latest Analyst Ratings For Legend Biotech
Via Benzinga
Assessing Legend Biotech: Insights From 15 Financial Analysts
Via Benzinga
Unveiling 18 Analyst Insights On Legend Biotech
Via Benzinga
Legend Biotech Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)
Via Benzinga
Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
Johnson & Johnson announced Phase 3 CARTITUDE-4 study results showing Carvykti significantly improves overall survival in relapsed or lenalidomide-refractory multiple myeloma after one prior line of... 
Via Benzinga
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
Legend Biotech analyst predicts growth for Carvykti. The Multiple Myeloma drug could become a $5B+ product. 
Via Benzinga
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts. 
Via Benzinga
Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months
In the last three months, IBRX outperformed NVDA by over 3x. 
Via Talk Markets
LEGN Stock Earnings: Legend Biotech Beats EPS, Misses Revenue for Q1 2024
LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.